| 21.09 -0.3 (-1.4%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.59 | 1-year : | 26.75 |
| Resists | First : | 21.91 | Second : | 22.9 |
| Pivot price | 21.41 |
|||
| Supports | First : | 20.29 | Second : | 16.88 |
| MAs | MA(5) : | 21.45 |
MA(20) : | 21.3 |
| MA(100) : | 22.49 |
MA(250) : | 23.34 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 42.9 |
D(3) : | 60.4 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 28.35 | Low : | 19.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACAD ] has closed above bottom band by 19.6%. Bollinger Bands are 62.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 21.58 - 21.69 | 21.69 - 21.78 |
| Low: | 20.8 - 20.91 | 20.91 - 21.01 |
| Close: | 20.92 - 21.1 | 21.1 - 21.25 |
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Sat, 13 Jun 2026
Precision Trading with Acadia Pharmaceuticals Inc. (ACAD) Risk Zones - Stock Traders Daily
Tue, 09 Jun 2026
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Show Mixed Recent Momentum - simplywall.st
Mon, 01 Jun 2026
ACADIA (NASDAQ: ACAD) director granted RSUs and stock options - Stock Titan
Mon, 01 Jun 2026
ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards - Stock Titan
Mon, 01 Jun 2026
ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant - Stock Titan
Fri, 29 May 2026
Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 171 (M) |
| Shares Float | 127 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 99 (%) |
| Shares Short | 11,750 (K) |
| Shares Short P.Month | 11,160 (K) |
| EPS | 2.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.3 |
| Profit Margin | 34.2 % |
| Operating Margin | -1.8 % |
| Return on Assets (ttm) | 3.6 % |
| Return on Equity (ttm) | 37.3 % |
| Qtrly Rev. Growth | 9.6 % |
| Gross Profit (p.s.) | 3.93 |
| Sales Per Share | 6.42 |
| EBITDA (p.s.) | 0.54 |
| Qtrly Earnings Growth | -81.9 % |
| Operating Cash Flow | 123 (M) |
| Levered Free Cash Flow | 154 (M) |
| PE Ratio | 9.54 |
| PEG Ratio | 50.8 |
| Price to Book value | 2.88 |
| Price to Sales | 3.28 |
| Price to Cash Flow | 29.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|